Table 1. Baseline characteristics of 650 patients with locoregionally advanced nasopharyngeal carcinoma.
Abbreviations: WHO = World Health Organization; yr = year; EBV = Epstein-Barr Virus.
| No-anemia | Anemia | ||
|---|---|---|---|
| 585(%) | 64(%) | P value | |
| Age(yr), | 0.479 | ||
| <45 | 315(53.8) | 32(49.2) | |
| ≥45 | 270(46.2) | 33(50.8) | |
| Gender | 0.006 | ||
| Female | 150(25.6) | 27(41.5) | |
| Male | 435(74.4) | 38(58.5) | |
| T stage | 0.927 | ||
| 1–2 | 141(24.1) | 16(24.6) | |
| 3–4 | 444(75.9) | 49(75.4) | |
| N stage | 0.063 | ||
| 0–1 | 323(55.2) | 28(43.1) | |
| 2–3 | 262(44.8) | 37(56.9) | |
| Clinical stage | 0.724 | ||
| 1–2 | 58(9.9) | 5(7.7) | |
| 3–4 | 527(90.1) | 60(92.3) | |
| WHO type | 0.350 | ||
| 2 | 29(5.0) | 1(1.5) | |
| 3 | 556(95.0) | 64(98.5) | |
| EBV DNA | 0.747 | ||
| ≥4000 | 357(61.0) | 41(63.1) | |
| <4000 | 228(39.0) | 24(36.9) | |
| Median follow-up months,median(range) | 48.9(1.3–85.5) | 50.2(2.5–84.0) | 0.706 |